Erasca Inc Dossier
Qualitative Analysis
Business overview
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage, precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The RAS/MAPK pathway is one of the most commonly mutated signaling cascades in human cancers, linked to approximately 5.5 million new cases annually worldwide. Erasca's pipeline is designed to comprehensively shut down this pathway using modality-agnostic programs. Its lead clinical-stage programs include ERAS-0015, a potentially best-in-class pan-RAS molecular glue, and ERAS-4001, a potentially first-in-class pan-KRAS reversible inhibitor.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Consolidating and executing a unified global development and commercialization strategy for lead candidates ERAS-0015 and ERAS-4001, following the acquisition of worldwide rights and successful capital raises.
Expected impact: Aims to establish ERAS-0015 as a best-in-class pan-RAS molecular glue and ERAS-4001 as a best-in-class pan-KRAS inhibitor globally.
Advancing clinical combination trials for ERAS-0015 with established therapies and novel agents to overcome resistance mechanisms and improve therapeutic durability in RAS-mutant solid tumors.
Expected impact: Synergistic clinical efficacy in combination with anti-EGFR (panitumumab), anti-PD-1 (KEYTRUDA), and PRMT5 inhibitors (vopimetostat).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Erasca exercised its option to expand the existing license agreement to include China, Hong Kong, and Macau, securing exclusive worldwide rights to the pan-RAS molecular glue ERAS-0015.
Terms: Erasca recorded a $150.0 million in-process R&D charge in Q1 2026 related to the option exercise and is obligated to make a one-time payment based on the development stage.
To evaluate ERAS-0015 in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in the AURORAS-1 clinical proof-of-concept study for RAS-mutant solid tumors.
Terms: Erasca sponsors and conducts the trial; Merck supplies KEYTRUDA at no cost.
To evaluate ERAS-0015 in combination with Tango's PRMT5 inhibitor vopimetostat (TNG462) in a Phase 1/2 trial for MTAP-deleted pancreatic cancer and MTAP-deleted RAS-mutant NSCLC.
Terms: Tango sponsors and conducts the trial; Erasca supplies ERAS-0015 at no cost. Mutually non-exclusive; both companies retain commercial rights.